HALOZYME THERAPEUTICS, INC. (HALO)
HALOZYME THERAPEUTICS, INC. (HALO) from its SEC filings: 2025 revenue $1.4 billion (+38% vs the year before), net margin 23%, free cash flow $644.6 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $1.4 billion |
| Revenue growth | +38% |
| Net income | $316.9 million |
| Net margin | 22.7% |
| Free cash flow | $644.6 million |
| Diluted EPS | $2.56 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +48% |
| Cash | $163.1 million |
| Long-term debt | $1.9 billion |
| Share count, 1 year | -3% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.